Infinity Pharmaceuticals Presents Product Updates and Announces 120th Patient Enrolled in DYNAMO Study on Indolent Non-Hodgkin Lymphoma
News
Earlier this month Infinity Pharmaceuticals presented updates on the clinical development and commercial strategy for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, during its Research and Development (R&D) Day. The ... Read more